Ironwood Pharmaceuticals (IRWD) Q2 2024 Earnings
IRWD·Reported August 8, 2024·Before market open
Ironwood Pharmaceuticals reported Q2 2024 revenue of $94.4M, missed analyst consensus of $107.0M by $12.6M. Diluted EPS came in at $-0.01, missed the $0.15 consensus by $0.16.
Revenue
$94.4Mmissed by $12.6M
Consensus: $107.0MDiluted EPS
$-0.01missed by $0.16
Consensus: $0.15
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Ironwood Pharmaceuticals's Q2 2024 earnings report.
Ironwood Pharmaceuticals (IRWD) reported Q2 2024 earnings on August 8, 2024 before market open.
Ironwood Pharmaceuticals reported revenue of $94.4M and diluted EPS of $-0.01 for Q2 2024.
Revenue missed the consensus estimate of $107.0M by $12.6M. EPS missed the consensus estimate of $0.15 by $0.16.
You can read the 10-Q periodic report (0001558370-24-011590) directly on SEC EDGAR. The filing index links above go to sec.gov.